aMean values bPre-radiotherapy levels are compared with healthy controls after adjusting for age and BMI cPre- and post- radiotherapy levels are compared dp < 0.001, ep < 0.05 n.a.a
= not available aMean values bPre-radiotherapy levels are compared with healthy controls after adjusting for age and BMI cPre- and post- radiotherapy levels are compared dp < 0.001, ep < 0.05 n.a.a
It is worth noting that the elevated levels we see during radiotherapy are higher (up to 80 mg/L), with the pre radiotherapy levels averaging 34 mg/mL.
Analysis of the levels seen before and during radiotherapy levels for LRG1, LBP and CRP in adenocarcinoma and small cell lung cancer showed no significant difference in values (Fig. 3d).
For patients with a grade 3 tumour, focalised postoperative radiotherapy (option, level of evidence: C) or follow-up (option) can be offered.
Irradiation should be targeted using conventional external-beam radiotherapy (standard, level of evidence: B1).
Patients with cervical lymph node metastases from squamous cell carcinoma should be offered lymph node dissection and complementary radiotherapy (standard, level of evidence: C).
In patients with incomplete resection and a grade 2 tumour, the treatment options are: follow-up, further resection or localised postoperative radiotherapy (options, level of evidence: C).
Only progressive tumours, as diagnosed from clinical symptoms and/or radiological images, should be treated with radiotherapy (option, level of evidence: C).
The patient's clinical status should be considered in any treatment decision (recommendation): Only progressive tumours, as diagnosed from clinical symptoms and/or radiological images, should be treated with radiotherapy (option, level of evidence: C).
